Verve Therapeutics, Inc. VERV
Set alert
11.13 0.00 0.00%
At close · Jul 25
11.13 Day range 11.13
52-week range unavailable
- YTD
- +97.34%
- 1 year
- +57.20%
- Open
- 11.13
- Prev close
- 11.13
- Mkt cap
- 499.52M
- Vol
- 10.31M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.13
- High
- 11.13
- Forward P/E
- -2.04
- Beta
- 1.76
- Short ratio
- 11.25
- Inst. own
- 97.87%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.76
- 200-d avg
- 6.48
- 1y target
- 26.20
Analyst view
Consensus: buy
Buy
Price target (mean) 26.20 +135.4% upside
Now 11.13
- Target (low)
- 14.00
- Target (mean)
- 26.20
- Target (high)
- 40.00
Ratings (0m) 10 8 buy · 2 hold · 0 sell
- Strong buy3
- Buy5
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 10
- 1 month ago 10
- 2 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.67322 | -0.80543 – -0.51 | -0.69 | +2.4% | 4.24M | -17.6% | 11 |
| Next quarter | -0.73286 | -0.87 – -0.60 | -0.59 | -24.2% | 3.17M | -44.3% | 7 |
| Current year | -2.45 | -2.82 – -1.89 | -3.12 | +21.6% | 23.44M | +99.4% | 12 |
| Next year | -2.92 | -3.61 – -2.28 | -2.45 | -19.5% | 13.41M | -42.8% | 10 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 6, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 6, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 12, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 9, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| May 9, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 3, 2024 | Stifel | Maintained | Buy | Buy |
| Feb 28, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Sep 13, 2023 | Cantor Fitzgerald | Reiterated | Neutral | Neutral |
| Aug 29, 2023 | Cantor Fitzgerald | Reiterated | Neutral | Neutral |
| Aug 15, 2023 | Guggenheim | Maintained | Buy | Buy |
| Aug 11, 2023 | Credit Suisse | Reiterated | Neutral | Neutral |
| Jun 16, 2023 | Canaccord Genuity | Reiterated | Buy | Buy |
| May 16, 2023 | RBC Capital | Reiterated | Outperform | Outperform |
| Apr 13, 2023 | Canaccord Genuity | Initiated | — | Buy |
| Feb 1, 2023 | Cantor Fitzgerald | Initiated | — | Neutral |
| Dec 15, 2022 | Goldman Sachs | Initiated | — | Sell |
| Nov 8, 2022 | RBC Capital | Maintained | — | Outperform |
| Oct 6, 2022 | Credit Suisse | Initiated | — | Neutral |
| Aug 25, 2022 | Stifel | Upgrade | Hold | Buy |
| Jul 18, 2022 | BMO Capital | Maintained | — | Outperform |
| Jun 17, 2022 | BMO Capital | Initiated | — | Outperform |
| Feb 18, 2022 | RBC Capital | Initiated | — | Outperform |
| Sep 24, 2021 | Stifel | Initiated | — | Hold |
| Jul 12, 2021 | William Blair | Initiated | — | Outperform |
| Jul 12, 2021 | Guggenheim | Initiated | — | Buy |
| Jul 12, 2021 | JP Morgan | Initiated | — | Neutral |
| Jul 12, 2021 | Jefferies | Initiated | — | Buy |